1 Signaling Pathways of Type I and Type III Interferons and Targeted Therapies in Systemic Lupus Erythematosus.

2 Impact of Repetitive Text Messages on Retention of Knowledge.

3 Zika Virus NS3 Mimics a Cellular 14-3-3-Binding Motif to Antagonize RIG-I- and MDA5-Mediated Innate Immunity.

4 ifn-dependent and -independent reduction in west nile virus infectivity in human dermal fibroblasts

5 predictors of the efficiency of short-term interferon-containing therapy using direct-acting antiviral drugs in patients with chronic hepatitis c virus genotype 1

6 the effect of antiviral substance 6-(2-morpholin-4-yl-ethyl)-6h-indolo [2,3-b]quinoxaline upon biomarkers of inflammation

7 predictors of spontaneous viral clearance and outcomes of acute hepatitis c infection

8 retrospective evaluation of hairy cell leukemia patients treated with three different first-line treatment modalities in the last two decades: a single-center experience

9 studies on the replication of mayaro virus grown in interferon treated cells

10 factors associated with treatment interruption for hepatitis c

11 the treatment outcome and impact on blood transfusion demand of peg-interferon/ribavirin in thalassemic patients with chronic hepatitis c

12 increased oral lichen planus in a chronic hepatitis patient associated with elevated transaminase levels before and after interferon/ribavirin therapy

13 virus infection triggers mavs polymers of distinct molecular weight

14 a better antiviral efficacy found in nucleos(t)ide analog (na) combinations with interferon therapy than na monotherapy for hbeag positive chronic hepatitis b: a meta-analysis

15 role of type i and ii interferons in colorectal cancer and melanoma

16 cytokines and stats in liver fibrosis

17 the dual role of exosomes in hepatitis a and c virus transmission and viral immune activation

18 immunotherapy for metastatic kidney cancer: its role at the present stage and prospects for clinical application

19 diagnóstico in vivo da asma brônquica

20 gamma interferon: from antimicrobial activity to immune regulation

21 MYC controls STING levels to downregulate inflammatory signaling in breast cancer cells upon DNA damage.

22 Targeting of COPⅠ elicits CD8 T cell-mediated anti-tumor immunity and suppresses growth of intrahepatic cholangiocarcinoma.

23 Blockade Effects of Anti-Interferon- (IFN-) Autoantibodies on IFN--Regulated Antimicrobial Immunity.

24 The benzoxathiolone LYR-71 down-regulates interferon-gamma-inducible pro-inflammatory genes by uncoupling tyrosine phosphorylation of STAT-1 in macrophages.

25 Morphea induced by treatment with Interferon β-1α.

26 Grazoprevir/elbasvir in peginterferon alfa plus ribavirin experienced patients with chronic genotype 1 HCV/HIV co-infection: a non-randomized, open-label clinical trial

27 Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B

28 Entecavir add-on or switch-to pegylated interferon improves HBsAg clearance in HBe antigen negative chronic hepatitis B patients

29 Higher baseline viral diversity correlates with lower HBsAg decline following PEGylated interferon-alpha therapy in patients with HBeAg-positive chronic hepatitis B

30 Pegylated-interferon plus ribavirin treatment does not alter the prevalence of resistance-associated substitutions to direct-acting antivirals in HCV genotype 1a patients

31 Grazoprevir/elbasvir in peginterferon alfa plus ribavirin experienced patients with chronic genotype 1 HCV/HIV co-infection: a non-randomized, open-label clinical trial

32 Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B

33 Entecavir add-on or switch-to pegylated interferon improves HBsAg clearance in HBe antigen negative chronic hepatitis B patients

34 Higher baseline viral diversity correlates with lower HBsAg decline following PEGylated interferon-alpha therapy in patients with HBeAg-positive chronic hepatitis B

35 Pegylated-interferon plus ribavirin treatment does not alter the prevalence of resistance-associated substitutions to direct-acting antivirals in HCV genotype 1a patients

36 Association of glycemic status and interferon-γ production with leukocytes and platelet indices alterations in type2 diabetes

37 Interferon-inducible protein (IFI) 16 regulates Chikungunya and Zika virus infection in human skin fibroblasts.

38 The application of HPLC/MS analysis with a multi-enzyme digest strategy to characterize different interferon product variants produced from Pichia pastoris.

39 Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals.

40 Interferon-γ and interleukin-12 production in relation to gene polymorphisms in BCG osteitis.

41 Pulmonary arterial hypertension in interferonophaties: a case report and a review of the literature.

42 Human host genetic factors in nontuberculous mycobacterial infection: lessons from single gene disorders affecting innate and adaptive immunity and lessons from molecular defects in interferon-γ-dependent signaling

43 Oxidative Modification of Blood Serum Proteins in Multiple Sclerosis after Interferon Beta and Melatonin Treatment

44 Knockdown of menin affects pre-mRNA processing and promoter fidelity at the interferon-gamma inducible <it>IRF1 </it>gene

45 Regulatory effect of recombinant human interferon α1b lozenges on immune function of rats

46 Identification of a systemic interferon-γ inducible antimicrobial gene signature in leprosy patients undergoing reversal reaction.

47 An easy and reliable strategy for making type I interferon signature analysis comparable among research centers

48 Novel glycosylated human interferon alpha 2b expressed in glycoengineered Pichia pastoris and its biological activity: N-linked glycoengineering approach.

49 Changes of liver fibrosis in chronic hepatitis C patients with no response to interferon-alpha therapy: including quantitative assessment by a morphometric method.

50 Pegylated versus non-pegylated interferon beta 1a in patients with relapsing-remitting multiple sclerosis: A cost-effectiveness analysis.

51 RIG-I is responsible for activation of type i interferon pathway in Seneca Valley virus-infected porcine cells to suppress viral replication 11 Medical and Health Sciences 1108 Medical Microbiology 11 Medical and Health Sciences 1107 Immunology

52 NOS1 inhibits the interferon response of cancer cells by S-nitrosylation of HDAC2.

53 Quantitative Interferon Gamma Release Assay and Tuberculin Skin Test Results to Predict Incident Tuberculosis: A Prospective Cohort Study.

54 Proportions of interferon-γ-producing ascites lymphocytes in response to mycobacterial antigens: A help for early diagnosis of peritoneal tuberculosis in a low TB incidence country

55 Pulmonary immune-compartment-specific interferon gamma responses in HIV-infected individuals with active tuberculosis (TB) in an area of high TB prevalence

56 Interferon-gamma release assay performance in northeastern Brazil: influence of the IFNG + 874 A>T polymorphism

57 Interferonγ/IL10 ratio defines the disease severity in pulmonary and extra pulmonary tuberculosis

58 Neuromyelitis optica in patients with increased interferon alpha concentrations.

59 Detection of native interferon-γ in nyala (Tragelaphus angasii): Towards diagnosing tuberculosis.

60 A model of skin inflammation in humans leads to a rapid and reproducible increase in the interferon response signature: a potential translational model for drug development.

61 Identification of a novel splice variant isoform of interferon regulatory factor 10, IRF10, in orange spotted grouper Epinephelus coioides.

62 Relevance of Ebola virus VP35 homo-dimerization on the type I interferon cascade inhibition.

63 Interferon-free treatments in patients with hepatitis C genotype 1-4 infections in a real-world setting.

64 KIR2DS2 as predictor of thrombocytopenia secondary to pegylated interferon-alpha therapy.

65 Prediction of efficacy to pegylated interferon-α-2b plus ribavirin in patients with genotype 2 hepatitis C virus using viral response within 2 weeks.

66 Association of ITPA gene variation and serum ribavirin concentration with a decline in blood cell concentrations during pegylated interferon-alpha plus ribavirin therapy for chronic hepatitis C.

67 Enhanced Prevention of Breast Tumor Metastasis by Nanoparticle-Delivered Vitamin E in Combination with Interferon-Gamma.

68 Interferon-complement loop in transplant-associated thrombotic microangiopathy.

69 Single-cell analysis reveals sexually dimorphic repertoires of Interferon-γ and IL-17A producing T cells in salivary glands of Sjögren’s syndrome mice

70 (-)-Epigallocatechin-3-gallate induces interferon-λ2 expression to anti-influenza A virus in human bronchial epithelial cells (BEAS-2B) through p38 MAPK signaling pathway.

71 SARS-CoV-2 (Covid-19): Interferon-epsilon may be responsible of decreased mortality in females.

72 Type I Interferonopathies: from a Novel Concept to Targeted Therapeutics.

73 Effects of infectious bursal disease virus infection on interferon and antiviral gene expression in layer chicken bursa

74 Association of Early Interferon-γ Production with Immunity to Clinical Malaria: A Longitudinal Study among Papua New Guinean Children

75 Effective Combination Therapy Using Interferon-γ and Interleukin-2 for Disseminated Mycobacterium avium Complex Infection in a Pediatric Patient with AIDS

76 Catching up with important players in atherosclerosis: type I interferons and neutrophils

77 Interferon production in children with respiratory syncytial, influenza, and parainfluenza virus infections

78 Respiratory virus infection of peripheral blood monocytes: correlation with ageing of cells and interferon production in vitro

79 Pulmonary artery hypertension during interferon-α therapy for chronic myelogenous leukemia

80 Interferon in nasal secretions from infants with viral respiratory tract infections

81 interferon-gamma release assays and tuberculin skin testing for diagnosing latent mycobacterium tuberculosis infection in at-risk groups in poland

82 the interferon beta therapies for treatment of relapsing–remitting multiple sclerosis: are they equally efficacious? a comparative review of open-label studies evaluating the efficacy, safety, or dosing of different interferon beta formulations alone or in combination

83 survival benefits of interferon-based therapy in patients with recurrent hepatitis c after orthotopic liver transplantation

84 in vitro release of interferon-gamma from peripheral blood lymphocytes in cutaneous adverse drug reactions

85 type i interferon induced and antagonized by foot-and-mouth disease virus

86 causation of acute flaccid paralysis by myelitis and myositis in enterovirus-d68 infected mice deficient in interferon αβ/γ receptor deficient mice

87 presence of transcription factor oct4 limits interferon-tau expression during the pre-attachment period in sheep

88 intravesical bcg+interferon-α-2b in prevention of recurrence in transitional cell carcinoma of urinary bladder

89 interferon tiloron inductor usage in complex therapy at patients with community-acquired pneumonia

90 single-dose intranasal treatment with def201 (adenovirus vectored consensus interferon) prevents lethal disease due to rift valley fever virus challenge

91 application and interpretation of an interferon-gamma release assay: results of an audit in a canadian centre

92 review of the clinical evidence for interferon &beta; 1a (rebif&reg;) in the treatment of multiple sclerosis

93 a preliminary study of recombinant human interferon-α-2a activity against rabies virus in murine model

94 association of functional polymorphisms in interferon regulatory factor 2 (irf2) with susceptibility to systemic lupus erythematosus: a case-control association study.

95 budding of enveloped viruses: interferon-induced isg15—antivirus mechanisms targeting the release process

96 interferon gamma receptor: the beginning of the journey

97 interplay between sars-cov-2 and the type i interferon response.

98 interferon-γ triggers hepatic stellate cell-mediated immune regulation through mek/erk signaling pathway

99 lichen planus induced by pegylated interferon alfa-2a therapy in a patient monitored for delta hepatitis

100 use of a combination of Аvastin and low-dose interferon- α in the first-line treatment of metastatic renal-cell cancer

101 type i interferon-independent dendritic cell priming and antitumor t cell activation induced by a mycoplasma fermentans lipopeptide

Keyword Connections

Journals

Research Groups

Bibliographies